The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease

Qutaiba A. Tawfic, Ali S. Faris, Rajini Kausalya

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Context: Acute pain is one of the main causes of hospital admission in sickle cell disease, with variable intensity and unpredictable onset and duration. Objectives: We studied the role of a low-dose intravenous (IV) ketamine-midazolam combination in the management of severe painful sickle cell crisis. Methods: A retrospective analysis was performed with data from nine adult patients who were admitted to the intensive care unit with severe painful sickle cell crises not responding to high doses of IV morphine and other adjuvant analgesics. A ketamine-midazolam regimen was added to the ongoing opioids as an initial bolus of ketamine 0.25 mg/kg, followed by infusion of 0.2-0.25 mg/kg/h. A midazolam bolus of 1 mg followed by infusion of 0.5-1 mg/h was added to reduce ketamine emergence reactions. Reduction in morphine daily requirements and improvement in pain scores were the determinants of ketamine-midazolam effect. The t-tests were used for statistical analysis. Results: Nine patients were assessed, with mean age of 27 ± 11 years. Morphine requirement was significantly lower after adding the IV ketamine-midazolam regimen. The mean ± SD IV morphine requirement (milligram/day) in the pre-ketamine day (D0) was 145.6 ± 16.5, and it was 112 ± 12.2 on Day 1 (D1) of ketamine treatment (P = 0.007). The Numeric Rating Scale scores on D0 ranged from eight to ten (mean 9.1), but improved to range from five to seven (mean 5.7) on D1. There was a significant improvement in pain scores after adding ketamine-midazolam regimen (P = 0.01). Conclusion: Low-dose ketamine-midazolam IV infusion might be effective in reducing pain and opioid requirements in patients with sickle cell disease with severe painful crisis. Further controlled studies are required to prove this effect.

Original languageEnglish
Pages (from-to)334-340
Number of pages7
JournalJournal of Pain and Symptom Management
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Midazolam
Ketamine
Sickle Cell Anemia
Morphine
Pain
Opioid Analgesics
Acute Pain
Intravenous Infusions
Intensive Care Units
Analgesics

Keywords

  • ketamine
  • midazolam
  • pain management
  • painful crisis
  • Sickle cell disease

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Nursing(all)
  • Medicine(all)

Cite this

The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. / Tawfic, Qutaiba A.; Faris, Ali S.; Kausalya, Rajini.

In: Journal of Pain and Symptom Management, Vol. 47, No. 2, 02.2014, p. 334-340.

Research output: Contribution to journalArticle

@article{210c8513c76a4d0d9a5188ff54b0068d,
title = "The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease",
abstract = "Context: Acute pain is one of the main causes of hospital admission in sickle cell disease, with variable intensity and unpredictable onset and duration. Objectives: We studied the role of a low-dose intravenous (IV) ketamine-midazolam combination in the management of severe painful sickle cell crisis. Methods: A retrospective analysis was performed with data from nine adult patients who were admitted to the intensive care unit with severe painful sickle cell crises not responding to high doses of IV morphine and other adjuvant analgesics. A ketamine-midazolam regimen was added to the ongoing opioids as an initial bolus of ketamine 0.25 mg/kg, followed by infusion of 0.2-0.25 mg/kg/h. A midazolam bolus of 1 mg followed by infusion of 0.5-1 mg/h was added to reduce ketamine emergence reactions. Reduction in morphine daily requirements and improvement in pain scores were the determinants of ketamine-midazolam effect. The t-tests were used for statistical analysis. Results: Nine patients were assessed, with mean age of 27 ± 11 years. Morphine requirement was significantly lower after adding the IV ketamine-midazolam regimen. The mean ± SD IV morphine requirement (milligram/day) in the pre-ketamine day (D0) was 145.6 ± 16.5, and it was 112 ± 12.2 on Day 1 (D1) of ketamine treatment (P = 0.007). The Numeric Rating Scale scores on D0 ranged from eight to ten (mean 9.1), but improved to range from five to seven (mean 5.7) on D1. There was a significant improvement in pain scores after adding ketamine-midazolam regimen (P = 0.01). Conclusion: Low-dose ketamine-midazolam IV infusion might be effective in reducing pain and opioid requirements in patients with sickle cell disease with severe painful crisis. Further controlled studies are required to prove this effect.",
keywords = "ketamine, midazolam, pain management, painful crisis, Sickle cell disease",
author = "Tawfic, {Qutaiba A.} and Faris, {Ali S.} and Rajini Kausalya",
year = "2014",
month = "2",
doi = "10.1016/j.jpainsymman.2013.03.012",
language = "English",
volume = "47",
pages = "334--340",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease

AU - Tawfic, Qutaiba A.

AU - Faris, Ali S.

AU - Kausalya, Rajini

PY - 2014/2

Y1 - 2014/2

N2 - Context: Acute pain is one of the main causes of hospital admission in sickle cell disease, with variable intensity and unpredictable onset and duration. Objectives: We studied the role of a low-dose intravenous (IV) ketamine-midazolam combination in the management of severe painful sickle cell crisis. Methods: A retrospective analysis was performed with data from nine adult patients who were admitted to the intensive care unit with severe painful sickle cell crises not responding to high doses of IV morphine and other adjuvant analgesics. A ketamine-midazolam regimen was added to the ongoing opioids as an initial bolus of ketamine 0.25 mg/kg, followed by infusion of 0.2-0.25 mg/kg/h. A midazolam bolus of 1 mg followed by infusion of 0.5-1 mg/h was added to reduce ketamine emergence reactions. Reduction in morphine daily requirements and improvement in pain scores were the determinants of ketamine-midazolam effect. The t-tests were used for statistical analysis. Results: Nine patients were assessed, with mean age of 27 ± 11 years. Morphine requirement was significantly lower after adding the IV ketamine-midazolam regimen. The mean ± SD IV morphine requirement (milligram/day) in the pre-ketamine day (D0) was 145.6 ± 16.5, and it was 112 ± 12.2 on Day 1 (D1) of ketamine treatment (P = 0.007). The Numeric Rating Scale scores on D0 ranged from eight to ten (mean 9.1), but improved to range from five to seven (mean 5.7) on D1. There was a significant improvement in pain scores after adding ketamine-midazolam regimen (P = 0.01). Conclusion: Low-dose ketamine-midazolam IV infusion might be effective in reducing pain and opioid requirements in patients with sickle cell disease with severe painful crisis. Further controlled studies are required to prove this effect.

AB - Context: Acute pain is one of the main causes of hospital admission in sickle cell disease, with variable intensity and unpredictable onset and duration. Objectives: We studied the role of a low-dose intravenous (IV) ketamine-midazolam combination in the management of severe painful sickle cell crisis. Methods: A retrospective analysis was performed with data from nine adult patients who were admitted to the intensive care unit with severe painful sickle cell crises not responding to high doses of IV morphine and other adjuvant analgesics. A ketamine-midazolam regimen was added to the ongoing opioids as an initial bolus of ketamine 0.25 mg/kg, followed by infusion of 0.2-0.25 mg/kg/h. A midazolam bolus of 1 mg followed by infusion of 0.5-1 mg/h was added to reduce ketamine emergence reactions. Reduction in morphine daily requirements and improvement in pain scores were the determinants of ketamine-midazolam effect. The t-tests were used for statistical analysis. Results: Nine patients were assessed, with mean age of 27 ± 11 years. Morphine requirement was significantly lower after adding the IV ketamine-midazolam regimen. The mean ± SD IV morphine requirement (milligram/day) in the pre-ketamine day (D0) was 145.6 ± 16.5, and it was 112 ± 12.2 on Day 1 (D1) of ketamine treatment (P = 0.007). The Numeric Rating Scale scores on D0 ranged from eight to ten (mean 9.1), but improved to range from five to seven (mean 5.7) on D1. There was a significant improvement in pain scores after adding ketamine-midazolam regimen (P = 0.01). Conclusion: Low-dose ketamine-midazolam IV infusion might be effective in reducing pain and opioid requirements in patients with sickle cell disease with severe painful crisis. Further controlled studies are required to prove this effect.

KW - ketamine

KW - midazolam

KW - pain management

KW - painful crisis

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84893781764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893781764&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2013.03.012

DO - 10.1016/j.jpainsymman.2013.03.012

M3 - Article

VL - 47

SP - 334

EP - 340

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 2

ER -